Rivulet Media Inc (fka RIVU)

[Awchiro]

Regardless of all the dilution, the market cap is still under 5 million for a company on the cusp of Clinical trials, for an orphan category disease , and one with top notch scientists on their advisory board. The assumption is that a company becomes more and more valuable as it moves further along from pre-clinical to phase 1/2 to phase 3 and finally an approved commercial product. A company with a phase 1 candidate should be worth closer to 40 million market cap-IMO. At this PPS, it is priced as if the IND will be rejected rather than approved. So place your bets- buy if you think IND will be approved or sell if you think it will be denied. It is that simple.